Abstract:Epidermal keratinocytes synthesize and secrete α‐melanocyte stimulating hormone (α‐MSH) and adrenocorticotropic hormone (ACTH). These act as agonists of the melanocortin 1 receptor expressed on the cell surface of human melanocytes. Binding of these physiological agonists or synthetic α‐MSH analogs to human MC1R activates the cAMP pathway, leading to activation of transcription factors, mainly p53, MITF, and Nrf2. The downstream targets of these transcription factors enhance DNA repair and antioxidant capacities, promote melanocyte survival, and increase eumelanin synthesis. These pleotropic effects confer photoprotection and prevent vitiligo. The physiological role of α‐melanocyte stimulating hormone in regulating integumental pigmentation of many vertebrate species has been recognized since the 1960's. However, its physiological significance for human pigmentation remained enigmatic until the 1990's. α‐Melanocyte stimulating hormone and related melanocortins are synthesized locally in the skin, primarily by keratinocytes, in addition to the pituitary gland, and therefore act as paracrine factors for melanocytes. Human melanocytes express the melanocortin 1 receptor, which recognizes α‐melanocyte stimulating hormone and the related adrenocorticotropic hormone as agonists. This review summarizes the current knowledge of the pleotropic effects of the activated melanocortin 1 receptor that maintain human melanocyte homeostasis by regulating melanogenesis and the response to environmental stressors, mainly solar radiation. Certain allelic variants of the melanocortin 1 receptor gene are associated with specific pigmentary phenotypes in various human populations. Variants associated with red hair phenotype compromise the function of the encoded receptor. Activation of the human melanocortin 1 receptor regulates eumelanin synthesis and enhances DNA damage response of melanocytes to solar radiation and oxidative stressors. We describe how synthetic selective melanocortin 1 receptor agonists can be efficacious as sunless tanning agents, for treatment of vitiligo and photosensitivity disorders, and for prevention of skin cancer, including melanoma.

Melanogenesis Connection with Innate Immunity and Toll-Like Receptors

Toll‐like receptors 2 and 3 enhance melanogenesis and melanosome transport in human melanocytes

Cultured Human Melanocytes Express Functional Toll-like Receptors 2–4, 7 and 9

Toll-like Receptor 9 Regulates Melanogenesis Through NF-κB Activation

The Immune Characteristics of Melanocytes and Their Relationship with Ultraviolet Irradiatio

[Toll-Like Receptor 4 Activation Inhibits Melanogenesis in Melanocytes].

Journey through the spectacular landscape of melanocortin 1 receptor

Toll-Like Receptors: Role in Dermatological Disease

Signaling Pathways in Melanogenesis

Increased Expression of Toll-like Receptor 7 and 9 in Vitiligo Melanocytes: a Pilot Study

Increased MAPK and NF-κB Expression of Langerhans Cells is Dependent on TLR2 and TLR4, and Increased IRF-3 Expression is Partially Dependent on TLR4 Following UV Exposure

[Regulation of melanogenesis: the role of cAMP and MITF]

Diversified Stimuli-Induced Inflammatory Pathways Cause Skin Pigmentation

Recognition of Melanocytes in Immuno-Neuroendocrinology and Circadian Rhythms: Beyond the Conventional Melanin Synthesis

Human Melanocyte Biology, Toxicology, and Pathology

Toll-like receptors in skin infections and inflammatory diseases.

Differential expression of inflammatory cytokines and chemokines in lipopolysaccharide‐stimulated melanocytes from lightly and darkly pigmented skin

044 Oxidative Stress Inducing TRPM2 Activate the NLRP3 Inflammasome in Keratinocytes Resulting in Melanocyte Destruction in Vitiligo

UVB-Induced Secretion of IL-1 β Promotes Melanogenesis by Upregulating TYR/TRP-1 Expression In Vitro

Melanogenesis and the Targeted Therapy of Melanoma

Inhibition of melanogenesis by HLA class II molecules